Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab with or without tiragolumab after chemoradiotherapy in unresectable esophageal squamous cell carcinoma
jRCT2031200166Phase 3Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing Atezolizumab + tiragolumab, Atezolizumab + placebo and Placebo (3 arms). Started Nov 2020; status: active, not recruiting.
02
Drugs
atezolizumabtiragolumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on jRCT2031200166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200166.